Happy Thanksgiving! Save 50% on Your MarketBeat All Access Subscription.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.23 (-1.51%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.23 (-1.51%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.23 (-1.51%)
S&P 500   3,963.94 (-1.54%)
DOW   33,849.46 (-1.45%)
QQQ   282.71 (-1.47%)
AAPL   144.22 (-2.63%)
MSFT   241.76 (-2.32%)
META   108.78 (-2.36%)
GOOGL   96.05 (-1.45%)
AMZN   93.95 (+0.58%)
TSLA   182.92 (+0.03%)
NVDA   158.27 (-2.72%)
NIO   10.12 (-0.49%)
BABA   75.88 (+0.50%)
AMD   73.19 (-2.60%)
T   18.82 (-1.57%)
MU   55.75 (-4.55%)
CGC   3.40 (-7.10%)
F   13.73 (-2.49%)
GE   85.47 (-3.03%)
DIS   95.69 (-3.22%)
AMC   7.33 (-2.40%)
PYPL   79.93 (-0.19%)
PFE   49.57 (+0.73%)
NFLX   281.23 (-1.51%)
NASDAQ:OTIC

Otonomy - OTIC Stock Forecast, Price & News

$0.11
-0.01 (-6.63%)
(As of 11/28/2022 05:17 PM ET)
Add
Compare
Today's Range
$0.09
$0.11
50-Day Range
$0.08
$0.30
52-Week Range
$0.07
$2.59
Volume
6.02 million shs
Average Volume
1.38 million shs
Market Capitalization
$6.12 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.25

Otonomy MarketRank™ Forecast

Analyst Rating
Hold
2.33 Rating Score
Upside/​Downside
2,977.7% Upside
$3.25 Price Target
Short Interest
Healthy
1.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.40mentions of Otonomy in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.77) to ($0.62) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.19 out of 5 stars

OTIC stock logo

About Otonomy (NASDAQ:OTIC) Stock

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Receive OTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.

OTIC Stock News Headlines

Otonomy (NASDAQ:OTIC) Now Covered by Analysts at StockNews.com
See More Headlines
Receive OTIC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Otonomy and its competitors with MarketBeat's FREE daily newsletter.

OTIC Company Calendar

Last Earnings
11/10/2021
Today
11/28/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
2/27/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:OTIC
Employees
51
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$3.25
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$0.50
Forecasted Upside/Downside
+2,934.5%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Net Income
$-51,180,000.00
Pretax Margin
-150,065.70%

Debt

Sales & Book Value

Annual Sales
$130,000.00
Book Value
$0.97 per share

Miscellaneous

Free Float
51,952,000
Market Cap
$6.12 million
Optionable
Optionable
Beta
1.19

Key Executives

  • Dr. David Allen Weber (Age 62)
    Pres, CEO & Director
    Comp: $907.68k
  • Mr. Paul E. Cayer (Age 60)
    Chief Financial & Bus. Officer
    Comp: $598.22k
  • Dr. Allen F. Ryan Ph.D.
    Co-Founder and Member of the Advisory Panel
  • Dr. Rick Adam Friedman M.D.
    Ph.D., Co-Founder and Member of the Advisory Panel
  • Dr. Alan Charles Foster Ph.D. (Age 66)
    Chief Scientific Officer
  • Ms. Breianna Bowen
    VP of HR
  • Ms. Barbara M. Finn
    Sr. VP of Regulatory Affairs & Quality Assurance
  • Dr. Fabrice Piu Ph.D.
    Sr. VP of Preclinical Devel.
  • Mr. David Skarinsky
    Sr. VP of Clinical
  • Mr. James Branch CPA
    VP of Fin. & Controller













OTIC Stock - Frequently Asked Questions

Should I buy or sell Otonomy stock right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Otonomy in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" OTIC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OTIC, but not buy additional shares or sell existing shares.
View OTIC analyst ratings
or view top-rated stocks.

What is Otonomy's stock price forecast for 2023?

3 analysts have issued twelve-month price targets for Otonomy's stock. Their OTIC share price forecasts range from $0.50 to $6.00. On average, they predict the company's stock price to reach $3.25 in the next year. This suggests a possible upside of 3,055.3% from the stock's current price.
View analysts price targets for OTIC
or view top-rated stocks among Wall Street analysts.

How have OTIC shares performed in 2022?

Otonomy's stock was trading at $2.08 at the beginning of the year. Since then, OTIC shares have decreased by 95.0% and is now trading at $0.1030.
View the best growth stocks for 2022 here
.

Are investors shorting Otonomy?

Otonomy saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 817,400 shares, an increase of 218.4% from the October 31st total of 256,700 shares. Based on an average trading volume of 2,920,000 shares, the short-interest ratio is presently 0.3 days. Approximately 1.5% of the shares of the stock are short sold.
View Otonomy's Short Interest
.

When is Otonomy's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our OTIC earnings forecast
.

How were Otonomy's earnings last quarter?

Otonomy, Inc. (NASDAQ:OTIC) released its quarterly earnings data on Wednesday, November, 10th. The biopharmaceutical company reported ($0.19) earnings per share for the quarter, meeting analysts' consensus estimates of ($0.19). During the same period in the previous year, the company earned ($0.22) EPS.

What other stocks do shareholders of Otonomy own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Otonomy investors own include BMO Capital Markets (), Stifel Nicolaus (), Wunderlich (), Standpoint Research (), Duncan Williams (), Soleil Securities (), Sterne Agee CRT (), Robert W. Baird (), Wellington Shields () and Macquarie ().

What is Otonomy's stock symbol?

Otonomy trades on the NASDAQ under the ticker symbol "OTIC."

Who are Otonomy's major shareholders?

Otonomy's stock is owned by a number of retail and institutional investors. Top institutional investors include Point72 Asset Management L.P. (9.64%), Lynx1 Capital Management LP (4.06%), Dimensional Fund Advisors LP (0.67%), Requisite Capital Management LLC (0.26%), Two Sigma Investments LP (0.25%) and Cutler Group LLC CA (0.00%). Insiders that own company stock include David Allen Weber, Jay Lichter and Robert Michael Savel II.
View institutional ownership trends
.

How do I buy shares of Otonomy?

Shares of OTIC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Otonomy's stock price today?

One share of OTIC stock can currently be purchased for approximately $0.10.

How much money does Otonomy make?

Otonomy (NASDAQ:OTIC) has a market capitalization of $5.89 million and generates $130,000.00 in revenue each year. The biopharmaceutical company earns $-51,180,000.00 in net income (profit) each year or ($0.77) on an earnings per share basis.

How can I contact Otonomy?

Otonomy's mailing address is 4796 EXECUTIVE DRIVE, SAN DIEGO CA, 92121. The official website for the company is www.otonomy.com. The biopharmaceutical company can be reached via phone at (619) 323-2200, via email at ir@otonomy.com, or via fax at 619-291-9190.

This page (NASDAQ:OTIC) was last updated on 11/28/2022 by MarketBeat.com Staff